{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-018586","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2026-05-27T20:34:57+00:00","discovered_at":"2026-05-27T20:36:00.273925+00:00","generated_at":"2026-05-27T20:38:05.970465+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"TG Therapeutics announces positive Phase 3 ENHANCE trial results for BRIUMVI consolidated dosing","bullets":["Phase 3 ENHANCE trial met primary endpoint, demonstrating bioequivalent drug exposure between single 600 mg Day 1 infusion and approved 150 mg Day 1 + 450 mg Day 15 regimen.","Safety and tolerability of consolidated first infusion were consistent with established BRIUMVI profile; no Grade 3 or higher infusion reactions occurred.","Supplemental BLA submission targeted for second half of 2026 based on these results.","If approved, BRIUMVI would be the first and only IV anti-CD20 therapy initiated with a single infusion."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-018586","json":"https://secwatch.observer/filing/0001437749-26-018586.json","markdown":"https://secwatch.observer/filing/0001437749-26-018586.md","text":"https://secwatch.observer/filing/0001437749-26-018586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774926018586/0001437749-26-018586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774926018586/tgtx20260527_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-27T20:38:05.970465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001193125-26-251399","ticker":"IDYA","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2026-06-01T20:05:32+00:00","headline":"IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251399","json":"https://secwatch.observer/filing/0001193125-26-251399.json","markdown":"https://secwatch.observer/filing/0001193125-26-251399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/0001193125-26-251399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/d138848d8k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251394","ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2026-06-01T20:05:16+00:00","headline":"Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251394","json":"https://secwatch.observer/filing/0001193125-26-251394.json","markdown":"https://secwatch.observer/filing/0001193125-26-251394.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/0001193125-26-251394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/fulc-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001628280-26-039297","ticker":"GPRO","company_name":"GoPro, Inc.","filed_at":"2026-06-01T13:12:22+00:00","headline":"GoPro refiles financials with going-concern warning; potential defaults on debt","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039297","json":"https://secwatch.observer/filing/0001628280-26-039297.json","markdown":"https://secwatch.observer/filing/0001628280-26-039297.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500435/000162828026039297/0001628280-26-039297-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500435/000162828026039297/gpro-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063161","ticker":"OPTU","company_name":"Optimum Communications, Inc.","filed_at":"2026-06-01T12:16:33+00:00","headline":"Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt","event_type":"other_material","sec_items":["1.01","3.02","7.01","8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063161","json":"https://secwatch.observer/filing/0001213900-26-063161.json","markdown":"https://secwatch.observer/filing/0001213900-26-063161.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1702780/000121390026063161/0001213900-26-063161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1702780/000121390026063161/ea0292871-8k_optimum.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026534","ticker":"STSS","company_name":"Sharps Technology Inc.","filed_at":"2026-06-01T12:15:14+00:00","headline":"Sharps Technology rebrands as SkyAI, pivots to AI finance platform for Global South","event_type":"other_material","sec_items":["5.03","8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026534","json":"https://secwatch.observer/filing/0001493152-26-026534.json","markdown":"https://secwatch.observer/filing/0001493152-26-026534.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737995/000149315226026534/0001493152-26-026534-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737995/000149315226026534/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-249725","ticker":"EIKN","company_name":"Eikon Therapeutics, Inc.","filed_at":"2026-06-01T11:30:25+00:00","headline":"Eikon reports 63.1% ORR in Phase 2 NSCLC trial of EIK1001; PARP1 inhibitor EIK1003 shows 24.5% ORR with paclitaxel","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-249725","json":"https://secwatch.observer/filing/0001193125-26-249725.json","markdown":"https://secwatch.observer/filing/0001193125-26-249725.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/0001193125-26-249725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861123/000119312526249725/eikn-20260530.htm"},"side_by_side_evidence":null},{"accession":"0001750155-26-000080","ticker":"CWBHF","company_name":"Charlotte's Web Holdings, Inc.","filed_at":"2026-06-01T21:13:23+00:00","headline":"Charlotte's Web appoints BAT GC to board, closes debt conversion & US$10M investment","event_type":"other_material","sec_items":["5.02","5.07","8.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001750155-26-000080","json":"https://secwatch.observer/filing/0001750155-26-000080.json","markdown":"https://secwatch.observer/filing/0001750155-26-000080.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750155/000175015526000080/0001750155-26-000080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750155/000175015526000080/cweb-20260528.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063486","ticker":"MDAI","company_name":"Spectral AI, Inc.","filed_at":"2026-06-01T20:01:42+00:00","headline":"Spectral AI gets FDA clearance for DeepView burn indication; targets first commercial sales by year-end 2026","event_type":"other_material","sec_items":["5.07","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063486","json":"https://secwatch.observer/filing/0001213900-26-063486.json","markdown":"https://secwatch.observer/filing/0001213900-26-063486.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833498/000121390026063486/0001213900-26-063486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833498/000121390026063486/ea0292962-8k_spectral.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}